Emicizumab promotes factor Xa generation on endothelial cells

• Published in: Journal of thrombosis and haemostasis Vol. 22; no. 6; pp. 1605 - 1615
• Main Authors: Fager, Ammon M., Ellsworth, Patrick, Key, Nigel S., Monroe, Dougald M., Hoffman, Maureane
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2024
• Subjects: coagulation; emicizumab; endothelium; factor IXa; factor VIIIa; hemophilia; emicizumab; endothelium; hemophilia; factor IXa; coagulation; factor VIIIa
• ISSN: 1538-7836; 1538-7836
• DOI: 10.1016/j.jtha.2024.02.017

Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mimics FVIIIa, has revolutionized the treatment of these patients. However, the use of an activated prothrombin complex concentrate [FEIBA (Takeda)] to treat breakthrough bleeding in patients on emicizumab has been associated with thrombotic complications including a unique microangiopathy. We hypothesized that the thrombotic complications observed with the combination of emicizumab and FEIBA might be due to excessive expression of procoagulant activity on the surface of endothelial cells. We examined the ability of emicizumab to promote FX activation on endothelial cells using 2 cell culture models. We found that endothelial cells readily support emicizumab-mediated activation of FX by FIXa. The level of FXa generation depends on the concentration of available FIXa. The addition of FEIBA to emicizumab increased FXa generation in a dose-dependent manner on endothelial cells in both models. The rate of FXa generation was further enhanced by endothelial cell activation. However, unlike emicizumab, we found limited FXa generation in the presence of FVIII(a), which followed a significant lag time and was not dependent on FIXa concentration under these conditions. Emicizumab promotes FXa generation on the surface of endothelial cells, which is markedly enhanced in the presence of FEIBA. These findings demonstrate a potential mechanism for the thrombotic complications seen with the combined use of emicizumab and FEIBA.